Oruka Therapeutics Shares Soar 16.1% on Executive Promotion, Index Inclusion

Oruka Therapeutics, Inc. (NasdaqGM:ORKA) shares surged 16.1% in pre-market trading on July 2, 2025, driven by a series of positive developments and strategic moves within the company.

Oruka Therapeutics, Inc., formerly known as ARCA biopharma, Inc., is a biotechnology company focused on developing novel biologics for the treatment of chronic skin diseases, with a particular emphasis on plaque psoriasis. The company's portfolio includes ORKA-001 and ORKA-002, two lead programs designed to block cytokines involved in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19), while ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).

Recently, Oruka Therapeutics, Inc. announced the promotion of Laura, a key executive, which has been well-received by investors. Additionally, the company has been added to the Russell 3000 Value Index and the Russell 2500 Value Index, further enhancing its market visibility and credibility. These strategic moves and positive developments have contributed to the significant pre-market surge in the company's stock price.